{"title":"再挑战布伦妥昔单抗维多汀对难治性真菌病有效：一份病例报告","authors":"Hikaru Kawahara, Etsuko Okada, Yu Sawada","doi":"10.3389/jcia.2024.12474","DOIUrl":null,"url":null,"abstract":"Mycosis fungoides (MF) is a type of primary cutaneous T-cell lymphoma. The anti-cluster of differentiation (CD) 30 antibody agent, brentuximab vedotin (BV), has recently been developed for specific targets against CD30-expressed tumor cells with high efficacy against various lymphomas. Herein, we present a case of marginally CD30-expressed MF successfully treated with BV rechallenge.","PeriodicalId":508694,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"20 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Rechallenge of brentuximab vedotin was effective for refractory mycosis fungoides: a case report\",\"authors\":\"Hikaru Kawahara, Etsuko Okada, Yu Sawada\",\"doi\":\"10.3389/jcia.2024.12474\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mycosis fungoides (MF) is a type of primary cutaneous T-cell lymphoma. The anti-cluster of differentiation (CD) 30 antibody agent, brentuximab vedotin (BV), has recently been developed for specific targets against CD30-expressed tumor cells with high efficacy against various lymphomas. Herein, we present a case of marginally CD30-expressed MF successfully treated with BV rechallenge.\",\"PeriodicalId\":508694,\"journal\":{\"name\":\"Journal of Cutaneous Immunology and Allergy\",\"volume\":\"20 12\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous Immunology and Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3389/jcia.2024.12474\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/jcia.2024.12474","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Rechallenge of brentuximab vedotin was effective for refractory mycosis fungoides: a case report
Mycosis fungoides (MF) is a type of primary cutaneous T-cell lymphoma. The anti-cluster of differentiation (CD) 30 antibody agent, brentuximab vedotin (BV), has recently been developed for specific targets against CD30-expressed tumor cells with high efficacy against various lymphomas. Herein, we present a case of marginally CD30-expressed MF successfully treated with BV rechallenge.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
